Departamento de Medicina Integrada, Universidade Federal do Rio Grande do Norte, Natal, RN, Brasil.
Hospital Monsenhor Walfredo Gurgel, Natal, RN, Brasil.
J Bras Nefrol. 2020 Mar;42(1):53-58. doi: 10.1590/2175-8239-JBN-2019-0108. Epub 2019 Oct 24.
Invasive procedures performed by trained nephrologists can reduce delays in making a definitive vascular access, complications, number of procedures on the same patient, and costs for the Public Health System.
to demonstrate that a long-term tunneled central venous catheter (LTCVC) implanted by a nephrologist is safe, effective, and associated with excellent results.
A retrospective study analyzed 149 consecutively performed temporary-to-long-term tunneled central venous catheter conversions in the operating room (OR) from a dialysis facility from March 2014 to September 2017. The data collected consisted of the total procedures performed, demographic characteristics of the study population, rates of success, aborted procedure, failure, complications, and catheter survival, and costs.
the main causes of end stage renal disease (ESRD) were systemic arterial hypertension and diabetes mellitus, 37.9% each. Patients had a high number of previous arteriovenous fistula (1.72 ± 0.84) and temporary catheter (2.87 ± 1.9) attempts until a definitive vascular access was achieved, while the preferred vascular site was right internal jugular vein (80%). Success, abortion, and failure rates were 93.3%, 2.7% and 4%, respectively, with only 5.36% of complications (minors). Overall LTCVC survival rates over 1, 3, 6, and 12 months were 93.38, 71.81, 54.36, and 30.2%, respectively, with a mean of 298 ± 280 days (median 198 days). The procedure cost was around 496 dollars. Catheter dysfunction was the main reason for catheter removal (34%).
Our analysis shows that placement of LTCVC by a nephrologist in an OR of a dialysis center is effective, safe, and results in substantial cost savings.
经过培训的肾病医生进行的有创操作可以减少确定血管通路的时间延误、减少并发症、减少同一患者的操作次数,并降低公共卫生系统的成本。
证明由肾病医生植入的长期隧道中心静脉导管(LTCVC)是安全、有效且结果优异的。
回顾性研究分析了 2014 年 3 月至 2017 年 9 月在透析中心手术室进行的 149 例连续临时至长期隧道中心静脉导管转换。收集的数据包括总操作次数、研究人群的人口统计学特征、成功率、中止手术、失败、并发症和导管存活率以及成本。
终末期肾病(ESRD)的主要病因是系统性动脉高血压和糖尿病,各占 37.9%。患者在获得最终血管通路之前,有大量的动静脉瘘(1.72 ± 0.84)和临时导管(2.87 ± 1.9)尝试,首选血管部位为右颈内静脉(80%)。成功率、中止率和失败率分别为 93.3%、2.7%和 4%,并发症发生率仅为 5.36%(轻微)。1、3、6 和 12 个月的 LTCVC 总存活率分别为 93.38%、71.81%、54.36%和 30.2%,平均(中位数 198 天)为 298 ± 280 天。手术费用约为 496 美元。导管功能障碍是导管移除的主要原因(34%)。
我们的分析表明,肾病医生在透析中心手术室进行 LTCVC 置管操作是有效、安全的,并且可以节省大量成本。